Burgdorf – Ypsomed Canada, a subsidiary of Ypsomed A.G has received Health Canada approval for the YpsoPump insulin pump. The market entry in Canada is another important milestone in the consistently pursued global growth strategy of the parent company.
With its market approval and imminent launch into the Canadian market, Ypsomed is once again demonstrating its global growth strategy by opening up another large sales market for its own manufactured products, in particular for the insulin pump YpsoPump®. Canada, with a population of around 37 million people represents a large growth opportunity for Ypsomed. With a favorable healthcare reimbursement landscape and a reasonable adoption rate to the therapy, Ypsomed Canada intends to lead the industry with innovative and smart technology coupled with a patient 1st approach to our customers now and in the future. With the market launch of YpsoPump®, Ypsomed is gaining a foothold in North America.